Markets happy with Novartis's delivery
04/02/26 -"The Q4 performance, even though subdued, ensured that Novartis met the management’s 2025 guidance. Healthy Q4 growth across most key areas was largely offset by the generic erosion of the heart ..."
Pages
67
Language
English
Published on
04/02/26
You may also be interested by these reports :
04/02/26
The Q4 performance, even though subdued, ensured that Novartis met the management’s 2025 guidance. Healthy Q4 growth across most key areas was ...
04/02/26
Even though the Q4 performance ensured that Novo delivered on the lowered 2025 expectations, the markets seem frustrated with the 2026 outlook, ...
03/02/26
Roche’s shares have recovered c.34% in the last three months and are now close to the highs witnessed in April 2022, as investors eventually recover ...
29/01/26
The 2025 performance delivered on the management’s guidance, backed by a strong showing from the cornerstone immunology medicine Dupixent, newly ...